Keywords: Alzheimer's Disease, Molecular Imaging
Motivation: Glutamate (Glu) and gamma-aminobutyric acid (GABA) imbalance plays a significant role in Alzheimer's disease (AD) pathogenesis. Whether riluzole can improve neurotransmitter homeostasis in AD brain remains unclear.
Goal(s): Using CEST imaging and 1H-MRS to monitor Glu/GABA changes in riluzole-treated AD mice and evaluate riluzole's efficacy and mechanism.
Approach: Measured Glu/GABA levels using GluCEST, GABACEST, and 1H-MRS in riluzole-treated 3xTg AD mice. Assessed cognition brain pathology, neuronal survival, and protein expression.
Results: Riluzole increased GluCEST/GABACEST signals, elevated Glu/GABA levels in AD mice, correlating with improved cognition. Riluzole reduced AD-related pathology, increased neuronal survival, and restored Glu/GABA-related protein expression.
Impact: This study highlights the potential of combining CEST imaging and 1H-MRS as a non-invasive approach to evaluate riluzole’s effects on Glu/GABA metabolism and cognitive function in AD mice, providing a promising neuroimaging tool for assessing AD therapies.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords